IDO1 and neoplasm: antigen loss or decrease (potentially attributable to chemotherapy); 9/10 SD after 28 days; CAR T cell expansion; CAR T tumor infiltration; 20% transduction efficiency; IDO1, PD-L1, IL-10 upregulation post therapy;